Kaia Health, a startup providing app-based programs for musculoskeletal conditions and COPD, recently raised $75 million in funding. As competitors look to round out their platforms with other services, Kaia is looking to strike partnerships with clinicians.
The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.
Kaia Health, a startup making an app to help users manage back pain, touted the results of a large, randomized controlled trial using its app. The company currently markets its system to employers, but hopes to make it available as a covered benefit in the… Read More »Digital health startup Kaia hopes to win over insurers with results of back pain study